Drugs to treat H.I.V. and AIDS are being priced out of reach for many patients enrolled in insurance plans through the new health care exchanges, despite warnings that such practices are illegal under the Obama administration's health care law.
29 January 2015 | New York Times
The head of Gilead's German operations told the magazine that discounts from the list price of 60,000 euros (44,867 pounds) per treatment had been negotiated with four of Germany's statutory health insurers but declined to give the size of the discounts.
26 January 2015 | Yahoo News
Julio Cesar Cruz is an HIV patient and organizer with the Peruvian Network of Patients and Consumers . He participated in the demonstration and explained that, “The people who live with HIV in the country, are complaining that the Peruvian state is ...
21 January 2015 | TeleSUR
The latest issue of the Global Fund News Flash discusses the importance of dialogue and cooperation for achieving global health goals; reaching key populations with HIV prevention, treatment, and care services; and preventing malaria in Myanmar.
19 January 2015 | The Global Fund
Gilead has announced both the highest recorded prices ever for its direct acting hepatitis C antiviral, ledipasvir/sofosbuvir (Harvoni), and one of the most stringent anti-diversion programs ever devised. The price, highest in the U.S., comes in at a whopping US$94,000 for a 12-week course of treatment, with slightly lower prices in Europe.
19 January 2015 | The Body Pro
The NHS is to delay the introduction of a highly expensive drug that can save the lives of people infected with the hepatitis C virus. The move by NHS England is unprecedented, because the NHS rationing body, Nice (the National Institute for Health and Care Excellence) has approved the drug. Nice says sofosbuvir is cost-effective, because it is a cure for people who would otherwise run up huge NHS bills.
16 January 2015 | The Guardian
AbbVie has issued its guidance for 2015, and that guidance suggests that its newly launched hepatitis C drug cocktail, Viekira Pak, could be a big driver of earnings growth this year. In December, Viekira Pak received FDA approval as a treatment for hepatitis C genotype 1 after delivering compelling functional cure rates in the mid-90% range during clinical trials. That approval was highly anticipated by health care payers desperate for competition in this market, because hepatitis C market share leader Gilead Sciences' two hepatitis C drugs, Sovaldi and Harvoni, carry eye-popping price tags that are translating into billions of additional dollars in health care spending.
15 January 2015 | The Motley Fool
One of the costliest drugs on the market threatens the Veterans Affairs Department's health budget — to the point that the department, which added the medication to its formulary in April, provides it to only the sickest patients who need it.
09 January 2015 | USA Today
The Department of Health will be paying the lowest prices in the world in its next HIV/AIDS drug tender, despite not pushing prices down as far as it had hoped, it said on Monday.
07 January 2015 | Business Day
The Israeli Health Ministry will devote 100 million shekels (£16.6m), roughly a third of the NIS 324m (£53.7m). budget for additions to the 2015 health basket, to medications for treating viral hepatitis.
04 January 2015 | Jerusalem Post